Business
Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds
LITTLETON, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 1,982,356 shares originally issued in January 2023, November 2023 and February 20, 2024, at exercise pri
About this update from Vivos Therapeutics, Inc.
[{"type":"image","alt":"Vivos Therapeutics, Inc","displaySize":"","headline":null,"caption":"Vivos Therapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":148,"height":46,"url":"https://media.zenfs.com/en/globenewswire.com/452f3e3cd3796a0ed8557400112a2519"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/o.bVqaj5F3NG9.btjYGvyg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTY1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/452f3e3cd3796a0ed8557400112a2519","width":148,"height":46}},"lazy":false},{"type":"text","content":"LITTLETON, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 1,982,356 shares originally issued in January 2023, November 2023 and February 20, 2024, at exercise prices ranging from $3.83 to $5.05 per share, at a reduced exercise price of $2.34 per share. The shares of common stock issuable upon exercise of the warrants are registered for resale pursuant to an effective registration statement on Form S-3 (Registration No. 333- 278564). The gross proceeds to the company from the exercise of the warrants were approximately $4.64 million, prior to deducting placement agent fees and offering expenses.","length":939,"tagName":"p"},{"type":"text","content":"H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.","length":82,"tagName":"p"},{"type":"text","content":"As consideration for the exercise of such existing warrants for cash, the Company issued in a private placement new unregistered warrants to purchase up to an aggregate of 3,964,712 shares of common stock at an exercise price of $2.09 per share, which warrants are exercisable immediately upon issuance and, with respect to warrants to purchase up to 1,982,356 shares of common stock, will expire five years following the date of issuance, and with respect to warrants to purchase up to 1,982,356 shares of common stock, will expire twenty-four months following the date of issuance.","length":583,"tagName":"p"},{"type":"text","content":"Vivos intends to use the net proceeds from the offering for wor...